急性心肌梗死与冠状动脉血内皮细胞源微粒、组织因子和白细胞介素-33的相关性研究

袁玉娟; 李吉斌; 李昊; 穆叶赛·尼加提

doi:10.13201/j.issn.1001-1439.2021.04.008

急性心肌梗死与冠状动脉血内皮细胞源微粒、组织因子和白细胞介素-33的相关性研究

- 1. 新疆维吾尔自治区人民医院心血管内科 (乌鲁木齐,830001);
- 2. 新疆维吾尔自治区人民医院超声科;
- 3. 新疆维吾尔自治区人民医院急救中心
基金项目:
国家自然科学基金(No:81760068)

新疆维吾尔自治区人民医院院内项目(No:20190207)

详细信息

通讯作者: 穆叶赛·尼加提,E-mail:muyassar11@aliyun.com

中图分类号: R541.4

收稿日期: 2020-11-03

修回日期: 2020-12-16

Correlations between acute myocardial infarction and endothelial microparticles, tissue factor, and interleukin-33 of coronary artery blood

- 1. Department of Cardiology,People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830001, China;
- 2. Department of Ultrasound,People's Hospital of Xinjiang Uygur Autonomous Region;
- 3. Emergency Center,People's Hospital of Xinjiang Uygur Autonomous Region

More Information

Corresponding author: Muyesai·Nijiati, E-mail: muyassar11@aliyun.com

Received Date: 03 November 2020

Revised Date: 16 December 2020

摘要

摘要: 目的:分析急性心肌梗死(AMI)患者冠状动脉(冠脉)血内皮细胞源微粒(EMPs)、组织因子(TF)和白细胞介素-33(IL-33)水平,探讨EMPs、TF和IL-33与冠脉斑块局部急性血栓形成事件的相关性。方法:冠脉介入术中收集27例AMI患者(AMI组)和30例稳定型冠心病(SCAD)患者(SCAD组)冠脉血标本。采用流式细胞术对EMPs(CD31)进行定性和定量检测,采用ELISA法测定TF和IL-33蛋白水平。结果:AMI组EMPs水平高于SCAD组[11.10(8.27,13.20)%∶3.92(2.80,7.02)%,P<0.001],AMI组TF水平高于SCAD组[(303.80.12±42.04) pg/mL∶(197.12±38.05) pg/mL,P<0.001],AMI组IL-33水平高于SCAD组[(138.29±47.64) pg/mL∶(96.93±28.87) pg/mL,P<0.001]。根据ROC曲线分析EMPs、TF和IL-33诊断AMI的价值,其曲线下面积(AUC)分别为0.888、0.962和0.778。结论:AMI患者冠脉血EMPs、TF和IL-33蛋白水平升高,EMPs、TF蛋白和IL-33蛋白有可能参与急性冠脉血栓事件。
- 急性心肌梗死 /
- 内皮细胞源微粒 /
- 组织因子蛋白 /
- IL-33
Abstract: Objective: The study investigated the level of endothelial microparticles(EMPs), tissue factor(TF) and interleukin(IL)-33 protein of coronary blood in patients with acute myocardial infarction(AMI), and explored the correlations between EMPs, TF and IL-33.Methods: The level of EMPs, IL-33 and TF protein of coronary blood in AMI and stable coronary artery disease(SCAD) patients were tested by flow cytometry and ELISA.Results: In the study, we demonstrated that the AMI group had a higher level of EMPs, TF,and IL-33 protein than the SCAD patients in coronary blood(P<0.001), 11.10%(8.27%, 13.20%) vs 3.92%(2.80%, 7.02%) for EMPs,(303.80±42.04) pg/mL vs(197.12±38.05) pg/mL for TF protein,(138.29±47.64) pg/mL vs(96.93±28.87) pg/mL for IL-33 protein. According to the ROC curve analysis, the areas under the curve(AUC) EMPs, TF,and IL-33 protein were 0.888, 0.962 and 0.778.Conclusion: The coronary blood of level of EMPs, TF,and IL-33 protein in AMI patients may be involved in the process of acute thrombosis and become a potential risk factor for cardiovascular disease.
- acute myocardial infarction /
- coronary blood /
- endothelial microparticles /
- tissue factor

HTML全文

参考文献(32)

[1]	胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
[2]	Xu R,Greening DW,Zhu HJ,et al.Extracellular vesicle isolation and characterization:toward clinical application[J].J Clin Invest,2016,126(4):1152-1162.
[3]	Aberg M,Eriksson O,Siegbahn A.Tissue Factor NoncoagulantSignaling:Mechanisms and Implications for Cell Migration and Apoptosis[J].Semin Thromb Hemost,2015,41(7):691-699.
[4]	De Caterina R,Husted S,Wallentin L,et al.General mechanisms of coagulation and targets of anticoagulants(Section I).Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease[J].Thromb Haemost,2013,109(4),569-579.
[5]	Wilcox JN,Smith KM,Schwartz SM,et al.Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque[J].Proc Natl Acad Sci U SA,1989,86(8):2839-2843.
[6]	Breitenstein A,Tanner FC,Lüscher TF.Tissue factor and cardiovascular disease:quo vadis?[J].Circ J,2010,74(1):3-12.
[7]	Badimon L,Vilahur G.Thrombosis formation on atherosclerotic lesions and plaque rupture[J].J Intern Med,2014,276(6):618-632.
[8]	Demetz G,Seitz I,Stein A,et al.Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells[J].Atherosclerosis,2010,212(2):466-471.
[9]	Schmitz J,Owyang A,Oldham E,et al.IL-33,an interleukin-1-like cytokine that signals via the IL-1receptor-related protein ST2 and induces T helper type 2-associated cytokines[J].Immunity,2005,23(5):479-490.
[10]	Mirchandani AS,Salmond RJ,Liew FY.Interleukin-33and the function of innate lymphoid cells[J].Trends Immunol,2012,33(8):389-396.
[11]	Kakkar R,Hei H,Dobner S,et al.Interleukin 33as a mechanically responsive cytokine secreted by living cells[J].J Biol Chem,2012,287(9):6941-6948.
[12]	Demyanets S,Speidl WS,Tentzeris I,et al.Soluble ST2 and interleukin-33levels in coronary artery disease:relation to disease activity and adverse outcome[J].PLoS One,2014,9(4):e95055.
[13]	Dhillon OS,Narayan HK,Khan SQ,et al.Pre-discharge risk stratification in unselected STEMI:is there a role for ST2 or its natural ligand IL-33when compared with contemporary risk markers?[J].Int JCardiol,2013,167(5):2182-2188.
[14]	林捷,颜彦,施鸿毓.胸痛中心建设对急性心梗救治效率及预后影响的研究[J].临床急诊杂志,2019,20(10):767-770.
[15]	张新超,于学忠,陈凤英,等.急性冠脉综合征急诊快速诊治指南(2019)[J].临床急诊杂志,2019,20(4):253-262.
[16]	Gutiérrez E,Flammer AJ,Lerman LO,et al.Endothelial dysfunction over the course of coronary artery disease[J].Eur Heart J,2013,34(41):3175-3181.
[17]	Seki K,Sanada S,Kudinova AY,et al.Interleukin-33prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling[J].Circ Heart Fail,2009,2(6):684-691.
[18]	Koganti S,Eleftheriou D,Brogan PA,et al.Microparticles and their role in coronary artery disease[J].Int JCardiol,2017,230:339-345.
[19]	Vítková V,Živny J,Janota J.Endothelial cell-derived microvesicles:potential mediators and biomarkers of pathologic processes[J].Biomark Med,2018,12(2):161-175.
[20]	Edrissi H,Schock SC,Hakim AM,et al.Microparticles generated during chronic cerebral ischemia increase the permeability of microvascular endothelial barriers in vitro[J].Brain Res,2016,1634:83-93.
[21]	Yuan Y,Maitusong M,Muyesai N.Association of endothelial and red blood cell microparticles with acute myocardial infarction in Chinese:a retrospective study[J].Ann Palliat Med,2020,9(4):1564-1570.
[22]	袁玉娟,米日巴尼·买吐松,祖力批亚·艾力,等.急性心肌梗死患者外周血内皮细胞源微粒研究[J].临床心血管病杂志,2019,35(10):883-887.
[23]	Abbas M,Jesel L,Auger C,et al.Endothelial microparticles from acute coronary syndrome patients induce premature coronary artery endothelial cells ageing and thrombogenicity:role of the Ang II/AT1 receptor/NADPH oxidasemediated activation of MAPKs and PI3 kinase pathways[J].Circulation,2016,135(3):280-296.
[24]	van Es N,Bleker S,Sturk A,et al.Clinical Significance of Tissue Factor-Exposing Microparticles in Arterial and Venous Thrombosis[J].Semin Thromb Hemost,2015,41(7):718-727.
[25]	Annex BH,Denning SM,Channon KM,et al.Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes[J].Circulation,1995,91(3):619-622.
[26]	Mallat Z,Benamer H,Hugel B,et al.Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes[J].Circulation,2000,101(8):841-843.
[27]	Owens AP 3rd,Mackman N.Microparticles in hemostasis and thrombosis[J].Circ Res,2011,108(10):1284-1297.
[28]	Miller AM.Role of IL-33in inflammation and disease[J].J Inflamm(Lond),2011,8(1):22.
[29]	Stojkovic S,Kaun C,Heinz M,et al.Interleukin-33induces urokinase in humanendothelial cells-possible impact on angiogenesis[J].J Thromb Haemost,2014,12(6):948-957.
[30]	Demyanets S,Konya V,Kastl SP,et al.Interleukin-33induces expression of adhesionmolecules and inflammatory activation in human endothelial cells andin human atherosclerotic plaques[J].Arterioscler Thromb Vasc Biol,2011,31(9):2080-2089.
[31]	Stojkovic S,Kaun C,Basilio J,et al.Tissue factor is induced by interleukin-33inhuman endothelial cells:a new link between coagulation and inflammation[J].Sci Rep,2016,6:25171.
[32]	Choi YS,Choi HJ,Min JK,et al.Interleukin-33induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production[J].Blood,2009,114(14):3117-3126.